| Literature DB >> 31761230 |
Ana Lazaro-Carrillo1, Marco Filice2, María José Guillén3, Rebeca Amaro4, Mario Viñambres5, Andrea Tabero1, Karina Ovejero Paredes6, Angeles Villanueva7, Pilar Calvo3, Maria Del Puerto Morales4, Marzia Marciello8.
Abstract
Magnetic resonance imaging (MRI) is the most powerful technique for non-invasive diagnosis of human diseases and disorders. Properly designed contrast agents can be accumulated in the damaged zone and be internalized by cells, becoming interesting cellular MRI probes for disease tracking and monitoring. However, this approach is sometimes limited by the relaxation rates of contrast agents currently in clinical use, which show neither optimal pharmacokinetic parameters nor toxicity. In this work, a suitable contrast agent candidate, based on iron oxide nanoparticles (IONPs) coated with polyethyleneglycol, was finely designed, prepared and fully characterized under a physical, chemical and biological point of view. To stand out the real potential of our study, all the experiments were performed in comparison with Ferumoxytol, a FDA approved IONPs. IONPs with a core size of 15 nm and coated with polyethyleneglycol of 5 kDa (OD15-P5) resulted the best ones, being able to be uptaken by both tumoral cells and macrophages and showing no toxicity for in vitro and in vivo experiments. In vitro and in vivo MRI results for OD15-P5 showed r2 relaxivity values higher than Ferumoxitol. Furthermore, the injected OD15-P5 were completely retained at the tumor site for up to 24 h showing high potential as MRI contrast agents for real time long-lasting monitoring of the tumor evolution.Entities:
Keywords: Cancer diagnosis; Contrast agent; Endocytic mechanism; Intratumoral injection; Magnetic resonance molecular imaging; Pegylated iron oxide nanoparticles
Mesh:
Substances:
Year: 2019 PMID: 31761230 DOI: 10.1016/j.msec.2019.110262
Source DB: PubMed Journal: Mater Sci Eng C Mater Biol Appl ISSN: 0928-4931 Impact factor: 7.328